Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal Phase III study of Piclidenoson

Next Previous
X
Search
Trial Profile

Pivotal Phase III study of Piclidenoson

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COMFORT-2

    • Most Recent Events

    • 29 Jan 2024 According to a Can-Fite BioPharma media release, COMFORT 2 trial has been approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
    • 18 Dec 2023 According to a Can-Fite BioPharma media release, the company received a positive response from the U.S. Food and Drug Administration (FDA) on the Pediatric Study Plan for the treatment of children suffering from psoriasis with Piclidenoson. The plan has been submitted to allow enrollment of children with psoriasis to one or both of the Phase 3 studies.
    • 30 Nov 2023 According to a Can-Fite BioPharma media release, Phase III study in psoriasis is expected to commence soon.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top